CasNo.274901-16-5,Vildagliptin,(274901-16-5) Suppliers

1 Kilogram	Negotiable

Min.Order :1 Kilogram
Purity: 98%
Payment Terms : L/C,D/A,D/P,T/T,

Keywords

274901-16-5 Vildagliptin C16H15F6N5O?H3O4P?H2O

Quick Details

Appearance:White or off-white Solid
Application:Indications and Usage Vildagliptin (vildagliptin), developed by Novartis (Novartis) Pharmaceutical Co., Ltd, is another oral administrated inhibitor of Dipeptidyl peptidase-IV after sitagliptin (sitag
PackAge:According to the demand of customer
ProductionCapacity:20|Metric Ton|Year
Storage:Sealed, dry, microtherm , avoid light and smell.
Transportation:by air or by sea

Superiority:

The company has a professional R & D team, mature technology, very competitive prices and stable high quality products for customers to order high quality and low price product efforts!

Details:

Vildagliptin Basic information

Indications and Usage Mechanisms of Action Adverse reactions

Product Name:	Vildagliptin
Synonyms:	Vildagliptin (NVP-LAF 237);(-)-(2S)-1-[[(3-Hydroxytricyclo[3.3.1.1[3,7]]dec-1-yl)amino]acetyl]pyrrolidine-2-carbonitrile;Vildagliptin;2-Pyrrolidinecarbonitrile, 1-(((3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)amino)acetyl)-, (2S)-;Galvus;Laf 237;Unii-I6B4B2U96p;Vidagliptin (see vildagliptin)
CAS:	274901-16-5
MF:	C16H15F6N5OH3O4PH2O
MW:	303.4
EINECS:	1308068-626-2
Product Categories:	Amines;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Isotope Labelled Compounds;Metabolites & Impurities;API;Inhibitor;Galvus;Other APIs
Mol File:	274901-16-5.mol

Vildagliptin Chemical Properties

Melting point	153-155C
alpha	-78.3° (c = 9.73 in methanol)
density	1.27
Fp	275.1℃
storage temp.	-20°C Freezer
CAS DataBase Reference	274901-16-5(CAS DataBase Reference)

Safety Information

Risk Statements	28-38-41-48
Safety Statements	24/25-26-28-36/37/39
RIDADR	3077

MSDS Information

Vildagliptin Usage And Synthesis

Indications and Usage	Vildagliptin (vildagliptin), developed by Novartis (Novartis) Pharmaceutical Co., Ltd, is another oral administrated inhibitor of Dipeptidyl peptidase-IV after sitagliptin (sitagliptin). In 2008, it is approved for marketing in the European Union for the treatment of type 2 diabetes. Diabetes is a chronic metabolic disease with its prevalence being increased year by year. Type 2 diabetes is a complicated diseases caused with the combined action between polygenic genetic factors and environmental factors. Dipeptidyl peptidase IV (DPP-IV) inhibitors are a new class of anti-diabetic drugs which induces and facilitate the biosynthesis and secretion of insulin. It plays a role in lowering the blood carbohydrate concentration through multiple mechanisms such as inhibiting the β cell apoptosis, inhibiting glucagon secretion and reducing food intake. During its lowering effect on reducing blood carbohydrate levels, it can also reverse the situation of deteriorating function of pancreas islet for diabetic patients at the same time. Vildagliptin is the representative of drugs among the dipeptidyl peptidase inhibitor. It exhibited a good anti-diabetic effects and tolerance no matter whether it is being administered alone or in combination with metformin and insulin medication in clinical studies.
Mechanisms of Action	Vildagliptin is a selective, competitive and reversible DPP-4 inhibitor. Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 21 (GLP21) are important hormones that regulate body glucose concentration and have the same functions as intestinal insulin. Type-2 diabetes patients suffer from GIP insulin secretion failure, so only their GLP21 can promote insulin secretion by affecting receptors on islet beta cell membranes. GLP21 can also inhibit glucagon secretion and inhibit gastric clearing to extend the feeling of fullness (control appetite). DPP-4 binds with proteins in many types of tissues, including tissue in the kidney, liver, small intestine brush border, pancreatic duct, lymph cells, and endothelial cells, and it can deactivate GLP21 by hydrolyzing its N-terminal position-2 alanine. Vildagliptin binds with DPP-4 to produce a DPP-4 compound and inhibit its activity. It increases GLP21 concentration and promotes islet beta cells to produce insulin, while also lowering glucagon concentration, thus lowering blood sugar. Vildagliptin has not noticeable effects on weight.
Adverse reactions	Most common adverse reactions include headache, nasopharyngitis, coughing, constipation, dizziness and excess sweating. There have been very rare cases of hypotension, but it is unclear if conditions are related to this drug. Almost all research shows that the hypoglycemia occurrence rate while using Vildagliptin is similar to the rate when using a placebo. Control trials showed that compared to thiazolidinediones, Vildagliptin causes a similar occurrence rate of headaches, rashes, and other adverse reactions, but Vildagliptin has a lower occurrence rate of adverse reactions forcing patients to cease treatment and of severe adverse reactions.
Chemical Properties	White Solid